Imunon presents data from Phase 2 OVATION 2 clinical trial
IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced ...
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free ...